Three private equity consortiums are understood to be circling Dutch chemical company Akzo Nobel's drugs unit in a deal expected to raise about €8bn ($10.6bn).

In February, Akzo Nobel had said it would list 20% to 30% of the division, Organon, early this year and hired ABN Amro and Morgan Stanley as joint-bookrunners for the float.